Arbutus Biopharma announces the U.S. FDA has granted Fast Track designation to its imdusiran (AB-729) candidate for the treatment of chronic hepatitis B.
https://finviz.com/quote.ashx?t=ABUS&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.